🧠Oruen CNS Weekly Roundup: The Latest in CNS Medicine 🧠Â
The CNS field continues to evolve rapidly, with new developments emerging across psychiatry, neurology, and interventional neuroscience. This week’s roundup highlights key updates across multiple therapeutic areas.
Addiction
Brain stores relapse and recovery memories side by side
New research suggests alcohol relapse and recovery may be driven by separate competing memory traces in the brain. The findings could help inform future addiction treatments by strengthening recovery-related memory pathways.
Continue reading here:
https://medicalxpress.com/news/2026-04-brain-relapse-recovery-memories-side.html
Anxiety
GLP-1 receptor agonists linked to reduced anxiety and suicidality
New real-world evidence suggests GLP-1 receptor agonists may be associated with lower anxiety, reduced suicidality, and improved functioning in patients with type 2 diabetes and mental illness.
Continue reading here:
https://www.hcplive.com/view/glp-1-receptor-agonists-linked-reduced-anxiety-suicidality-mark-taylor-md
Depression
Lumateperone shows broad symptom benefit in MDD
HCPLive reports that adjunctive lumateperone 42 mg improved remission and helped relieve anxiety and sleep symptoms in patients with treatment-resistant major depressive disorder.
Continue reading here:
https://www.hcplive.com/view/lumateperone-shows-broad-symptom-benefit-for-mdd-with-michael-e-thase-md
Epilepsy
Phase 3 EPIC trial to evaluate NRTX-1001 cell therapy
NeurologyLive covers the phase 3 EPIC trial assessing NRTX-1001, an investigational cell therapy for drug-resistant mesial temporal lobe epilepsy. The study will assess seizure frequency reduction, safety, EEG outcomes, neurocognition, mood, and quality of life.
Continue reading here:
https://www.neurologylive.com/view/phase-3-epic-trial-evaluate-nrtx-1001-cell-therapy-drug-resistant-mesial-temporal-lobe-epilepsy
Multiple Sclerosis
Tolebrutinib falls short in phase 3 PERSEUS study
NeurologyLive reports that Sanofi’s tolebrutinib failed to meet key phase 3 endpoints in primary progressive multiple sclerosis, raising questions around its regulatory path and future positioning in MS care.
Continue reading here:
https://www.neurologylive.com/view/tolebrutinib-falls-short-phase-3-perseus-study-forcing-decision-redact-regulatory-submission
Neuro-oncology
Glioblastoma may disrupt brain-wide communication networks
Medical Xpress reports new findings showing that glioblastoma survival may be linked to how strongly the tumour affects large-scale white matter connections, reinforcing the view of glioblastoma as a network-disrupting disease rather than an isolated lesion.
Continue reading here:
https://medicalxpress.com/news/2026-04-glioblastoma-impact-brain-prognosis.html
Neuroscience / Neurosurgery
Researchers explore safer brain implant design
A new Medical Xpress report looks at how the brain reacts to implanted devices and how softer, more biocompatible materials may help reduce scarring and improve long-term implant performance.
Continue reading here:
https://medicalxpress.com/news/2026-04-subtle-science-safer-brain-implants.html
Pain
Neurobiologists map brain circuits tied to placebo pain relief
Researchers have identified brain circuitry involved in placebo pain relief, including endogenous opioid signalling pathways. The findings may help inform future non-opioid strategies for pain management.
Continue reading here:
https://medicalxpress.com/news/2026-04-neurobiologists-hack-brain-circuits-placebo.html